
Regeneron Pharmaceuticals (REGN) Stock
Genetics-driven biotech firm treating eye and immune diseases. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in November 2026.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It’s Moving

Regeneron Secures EU Approval for Flexible Libtayo Dosing, Bolstering Oncology Portfolio
- The European Commission approved an alternative flexible dosing regimen for Libtayo across skin, lung, and cervical cancer indications, allowing for administration every six weeks after initial treatment.
- New approvals include options to reduce subsequent infusion times by up to half, from 30 minutes to 15 minutes, potentially improving clinic throughput and patient experience.
- Executives highlighted that the company’s three largest growth drivers remain robust while preparing for a specialty drug launch and increased R&D spending, signaling continued operational momentum.

Regeneron Secures EU Approval for Flexible Libtayo Dosing, Bolstering Oncology Portfolio
- The European Commission approved an alternative flexible dosing regimen for Libtayo across skin, lung, and cervical cancer indications, allowing for administration every six weeks after initial treatment.
- New approvals include options to reduce subsequent infusion times by up to half, from 30 minutes to 15 minutes, potentially improving clinic throughput and patient experience.
- Executives highlighted that the company’s three largest growth drivers remain robust while preparing for a specialty drug launch and increased R&D spending, signaling continued operational momentum.
Six-Month Growth Performance
When is the next earnings date for REGENERON PHARMACEUTICALS INC (REGN)?
Regeneron Pharmaceuticals has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern of releasing results approximately three months after the prior quarter, the upcoming Q4 2026 earnings are expected in early February 2027. This anticipated timing aligns with their previous schedule, where reports were issued in early February and late January across recent years.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regeneron Pharmaceuticals' stock, expecting it to rise above its current price.
Financial Health
Regeneron is performing strongly with impressive profits, cash flow, and revenue generation.
Dividend
Regeneron’s low dividend yield of 0.39% indicates limited income potential. If you invested $1000 you would be paid $3.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.